Literature DB >> 11532348

Expression of IL-6 and IL-6 receptors by circulating clonotypic B cells in multiple myeloma: potential for autocrine and paracrine networks.

A J Szczepek1, A R Belch, L M Pilarski.   

Abstract

OBJECTIVE: To investigate the participation of clonotypic MM B cells in the IL-6 network in patients with multiple myeloma.
METHODS: CD19(+) B cells from 45 patients with multiple myeloma and from 18 healthy donors were sorted and their expression of IL-6, IL-6 receptor (CD126) characterized by flow cytometry, in situ RT-PCR, and ELISA measurement of IL-6 and soluble IL-6R. Expression of CD31 was detected by flow cytometry.
RESULTS: Interleukin-6 (IL-6) is a pleiotropic cytokine often overexpressed in multiple myeloma (MM). IL-6 induces growth and inhibits apoptosis of MM plasma cells, and upregulates the activity of osteoclasts. MM plasma cells, the most mature component of the MM clone, secrete IL-6 and induce IL-6 production from other cell types. However, the MM clone also includes circulating clonotypic B lymphocytes. Using ELISA and in situ RT-PCR we demonstrate here that, unlike the healthy control B cells, MM B cells express IL-6 mRNA and secrete IL-6 protein. In vitro, MM B cells were the major producers of IL-6 in peripheral blood mononuclear cells. On average, 50% of MM B cells express the IL-6 receptor (IL-6R, CD126), suggestive of autocrine stimulation. They also express CD31, potentially facilitating their paracrine interactions with osteoclast precursors.
CONCLUSION: Secretion of IL-6 by circulating clonotypic B cells in MM may contribute to the autocrine and paracrine cytokine networks that maintain the malignant clone and are responsible for disruption of normal bone metabolism in this incurable disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11532348     DOI: 10.1016/s0301-472x(01)00682-8

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  9 in total

1.  Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation.

Authors:  R Chakraborty; E Muchtar; S K Kumar; F K Buadi; D Dingli; A Dispenzieri; S R Hayman; W J Hogan; P Kapoor; M Q Lacy; N Leung; M A Gertz
Journal:  Bone Marrow Transplant       Date:  2017-11-13       Impact factor: 5.483

2.  IL-6 activates serum and glucocorticoid kinase via p38alpha mitogen-activated protein kinase pathway.

Authors:  Fanyin Meng; Yoko Yamagiwa; Silvia Taffetani; Jiahuai Han; Tushar Patel
Journal:  Am J Physiol Cell Physiol       Date:  2005-05-25       Impact factor: 4.249

3.  Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3.

Authors:  Erik A Nelson; Sarah R Walker; Alicia Kepich; Laurie B Gashin; Teru Hideshima; Hiroshi Ikeda; Dharminder Chauhan; Kenneth C Anderson; David A Frank
Journal:  Blood       Date:  2008-09-29       Impact factor: 22.113

4.  IκBε is a key regulator of B cell expansion by providing negative feedback on cRel and RelA in a stimulus-specific manner.

Authors:  Bryce N Alves; Rachel Tsui; Jonathan Almaden; Maxim N Shokhirev; Jeremy Davis-Turak; Jessica Fujimoto; Harry Birnbaum; Julia Ponomarenko; Alexander Hoffmann
Journal:  J Immunol       Date:  2014-03-03       Impact factor: 5.422

5.  Nonirradiated NOD/SCID-human chimeric animal model for primary human multiple myeloma: a potential in vivo culture system.

Authors:  Shang-Yi Huang; Hwei-Fang Tien; Fang-Hsein Su; Su-Ming Hsu
Journal:  Am J Pathol       Date:  2004-02       Impact factor: 4.307

6.  In multiple myeloma, bone-marrow lymphocytes harboring the same chromosomal abnormalities as autologous plasma cells predict poor survival.

Authors:  Carina S Debes Marun; Andrew R Belch; Linda M Pilarski
Journal:  Am J Hematol       Date:  2012-04-12       Impact factor: 10.047

7.  Multiple Myeloma Includes Phenotypically Defined Subsets of Clonotypic CD20+ B Cells that Persist During Treatment with Rituximab.

Authors:  Linda M Pilarski; Eva Baigorri; Michael J Mant; Patrick M Pilarski; Penelope Adamson; Heddy Zola; Andrew R Belch
Journal:  Clin Med Oncol       Date:  2008-03-27

8.  Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells.

Authors:  M Amit-Vazina; S Shishodia; D Harris; Q Van; M Wang; D Weber; R Alexanian; M Talpaz; B B Aggarwal; Z Estrov
Journal:  Br J Cancer       Date:  2005-07-11       Impact factor: 7.640

9.  Response to pneumococcal vaccination in multiple myeloma.

Authors:  Loïc Renaud; Susanna Schraen; Guillemette Fouquet; Stephanie Guidez; Hélène Demarquette; Morgane Nudel; Emilie Cayssials; Claire Bories; Charles Herbaux; Thomas Systchenko; Jean-Luc Faucompré; Antoine Machet; Florence Sabirou; Antony Levy; Arthur Bobin; Valentine Richez; Niels Moya; Cécile Gruchet; Deborah Desmier; Zoe van de Wyngaert; Benjamin Carpentier; Salomon Manier; Thierry Facon; Stephen Harding; Xavier Leleu
Journal:  Cancer Med       Date:  2019-05-30       Impact factor: 4.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.